



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 05 Dec 2016 (#42)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

## Important notices

- **NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice** ([NOT-AG-16-082](#))

### 1. Limited Competition: Clinical Trials in Organ Transplantation in Children (CTOT-C): Mechanistic Ancillary Studies

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([RFA-AI-16-078](#))

**Type:** U01

**Application Due Date:** March 15, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) solicits applications from currently funded Program Directors/Principal Investigators, Mechanistic Subcommittee members, core laboratory leaders and clinical site leaders in the "Clinical Trials in Organ Transplantation in Children (CTOT-C)" Program to support the conduct of studies of immune mechanisms using samples and clinical data collected from pediatric solid organ transplant recipients obtained in (a) ongoing or completed CTOT-C clinical studies, or (b) from other clinical trials in which the samples and data were collected with a demonstrably similar level of investigational rigor. Research supported under this FOA will focus on understanding graft dysfunction and/or loss and immune-mediated morbidity and mortality in pediatric transplant recipients. This FOA will leverage the samples and data gathered from CTOT-C's unique cohort of well-characterized patients, as well as the consortium infrastructure to carry out timely hypothesis-driven mechanistic studies. Successful ancillary mechanistic investigations will enhance the value of ongoing and completed CTOT-C projects, improve the research community's understanding of pediatric transplantation, and contribute to the identification of novel and robust surrogate endpoints for future interventional trials and/or novel therapeutic targets and biomarkers for diagnosis, treatment, and disease monitoring.

**Budget:** NIAID intends to commit \$3.46 million in FY 2018 to fund 6-10 awards. Application budgets are limited to \$400,000 direct costs/year. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

### 2. BRAIN Initiative: Targeted BRAIN Circuits Projects - TargetedBCP

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** ([RFA-NS-17-014](#))

**Type:** R01

**Application Due Date:** March 8, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

This FOA solicits applications for research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human animal species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior.

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$7M to fund 10 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 3. BRAIN Initiative: Exploratory Targeted BRAIN Circuits Projects - eTargetedBCP

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-NS-17-015\)](#)

**Type:** R21

**Application Due Date:** March 8, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

This FOA solicits applications for exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. Applications should offer a limited scope of aims and an approach that will establish feasibility, validity or other technically qualifying results that, if successful, would support a potential, subsequent Targeted Brain Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-17-014).

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$2M to fund 10 awards. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

### 4. Leveraging Existing Resources for Research on Lewy Body Dementia

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-NS-17-016\)](#)

**Type:** R03

**Application Due Date:** February 10, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this FOA is to invite research applications proposing to investigate the clinical, imaging, or physiological characteristics of subjects with **dementia and parkinsonism** (Lewy Body Dementia) using previously-collected data available in the Alzheimer's Disease Neuroimaging Initiative (ADNI)/National Alzheimer's Coordinating Center (NACC) and/or the Parkinson's Disease Biomarker Program (PDBP) databases. Research should focus on identifying clinical or biological attributes that could serve to 1) lead to early diagnosis, 2) improve differential diagnosis, and/or 3) lead to the identification of potential therapeutic targets. Applicants must propose to use data in at least one of the ADNI or PDBP databases, but may include the use of other previously-collected data if such data is scientifically relevant and of comparable quality. Applicants are not expected or encouraged to collect new data.

**Budget:** NINDS and NIA intend to commit \$1,000,000 in FY 2017 to fund 10-13 awards. A budget for direct costs of up to \$50,000 per year may be requested. The maximum project period is 2 years.

### 5. BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-NS-17-019\)](#)

**Type:** U01

**Application Due Date:** February 1, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

Invasive surgical procedures provide the unique ability to record and stimulate neurons within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and are rarely aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this FOA seeks applications to assemble integrated, multi-disciplinary teams to overcome these fundamental barriers. Projects should investigate high-impact questions in human neuroscience and disorders of the human nervous system. The research should be offered as experimental projects, or exploratory research and planning activities, for building teams, generating data and empirical results that will later compete for continued funding under new or ongoing FOAs of the BRAIN Initiative or under NIH Institute appropriations. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to brain recording and stimulating from invasive surgical procedures. Awardees will join a consortium work group, coordinated by the NIH, to identify consensus standards of practice as well as supplemental opportunities to collect and provide data for ancillary studies, and to aggregate and standardize data for dissemination among the wider scientific community.

**Budget:** NINDS and partner components intend to commit an estimated total of \$5.8M to fund 5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

### 6. Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PA-17-060\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. Observational studies should emphasize modifiable risk factors for future intervention research.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

## 7. Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PA-17-061\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. Observational studies should emphasize modifiable risk factors for future intervention research.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year. The maximum project period is 2 years.

## 8. Promoting Caregiver Health Using Self-Management

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PA-17-062\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

The purpose of this initiative is to stimulate research in promoting caregiver health using self-management. Caregiving is an important science area since the number of people living longer with chronic conditions is growing. Informal caregivers (lay caregivers) are defined as unpaid individuals (spouses, partners, family members, friends, or neighbors) involved in assisting others with activities of daily living and/or medical tasks. Formal caregivers are paid, delivering care in one's home or care settings (daycare, residential care facility). This concept focuses on informal caregivers.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

## 9. Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program

**Letter of Intent due date:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-17-063\)](#)

**Type:** X01

**Application Due Date:** March 7, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (to both Grants.gov and eRA Commons) on the application due date.

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

**Budget:** Not applicable; there are no funds associated with a resource access award. The scope of the proposed project should determine the project period. The maximum project period is 1 year.

**D71 - International Research Training Planning Grant:** To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

**D43 - International Research Training Grants:** To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

**R25 – NIH Education Projects:** used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

**R34 - Clinical Trial Planning Grant Program:** To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

**R35 - Outstanding Investigator Award:** To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U24 – Resource-Related Research Projects – Cooperative Agreements:** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U19 - Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

**Glossary of selected acronyms:**

<b>FOA</b>	Funding Opportunity Announcement
<b>PA</b>	Program Announcements ( <i>click on “PA” to search for further funding opportunities</i> )
<b>RFA</b>	Request for Applications ( <i>click on “RFA” to search for further funding opportunities</i> )

Complete [Glossary and acronym list of NIH Terms](#)

